Yuta Nagahisa, Toshiyuki Sumi, M. Sekikawa, K. Takeda, Keigo Matsuura, Hiroki Watanabe, Yuichi Yamada, Yoshiko Keira, H. Chiba
{"title":"Two Cases of ALK Fusion Gene-positive Lung Adenocarcinoma Treated with Brigatinib After Alectinib-induced Interstitial Lung Disease","authors":"Yuta Nagahisa, Toshiyuki Sumi, M. Sekikawa, K. Takeda, Keigo Matsuura, Hiroki Watanabe, Yuichi Yamada, Yoshiko Keira, H. Chiba","doi":"10.2482/haigan.62.1038","DOIUrl":null,"url":null,"abstract":"━━ Background. Alectinib is an effective and well-tolerated agent for treating anaplastic lymphoma kinase (ALK) fusion gene-positive lung adenocarcinoma. However, treatment with alectinib results in interstitial lung disease (ILD) as an adverse effect, thereby precluding therapy continuation. Several other ALK inhibitors have been studied in clinical trials","PeriodicalId":35081,"journal":{"name":"Japanese Journal of Lung Cancer","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Lung Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2482/haigan.62.1038","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1
Abstract
━━ Background. Alectinib is an effective and well-tolerated agent for treating anaplastic lymphoma kinase (ALK) fusion gene-positive lung adenocarcinoma. However, treatment with alectinib results in interstitial lung disease (ILD) as an adverse effect, thereby precluding therapy continuation. Several other ALK inhibitors have been studied in clinical trials
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
